Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Finding Study of SYL040012 in Glaucoma and Ocular Hypertension
NCT01739244Phase 2Completed
- Sponsor
- Sylentis
- Start
- Jul 2012
- Primary completion
- May 2013
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of bamosiran in ocular hypertension, open-angle glaucoma (OAG), sponsored by Sylentis. Started Jul 2012; status: completed.
02
Drugs
bamosiran
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT01739244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739244.